
    
      Multi-center, double blind, placebo-controlled study with parallel groups of outpatients with
      early, symptomatic Huntington's disease. Participants will be randomized to receive 1 gram
      twice daily (2 gram/day total daily dose) of active study drug or placebo. The 6-month
      placebo-controlled phased will be followed by a subsequent 6-month open-label extension phase
      with all subjects receiving 1 gram twice daily (2 grams/day total daily dose) of active study
      drug.
    
  